The startup claims its proprietary linker molecules can yield ADCs that are more precise and potent than existing options.
Side effects lead many patients to interrupt dosing of a drug regimen, allowing cancer to advance, said Mohit Trikha, president and chief operating officer of Kivu Bioscience. Kivu is developing ...
The World Health Organization reports that mpox cases are plateauing in Congo's South Kivu region, despite rising numbers in the rest of the country, Burundi, and Uganda. With fewer than 100 confirmed ...
Kamandi-Gite is situated approximately 130 kilometres from Goma City. Several reliable sources confirmed the presence of M23 ...
Some health officials say mpox cases in Congo appear to be “stabilizing.” It's a possible sign that the epidemic for which ...
San Francisco, USA-based biotech start-up Kivu Bioscience has announced the closing of a $92 million Series A financing round ...
Kivu Bioscience是一家癌症靶向药物研发商，该公司专有的linker-payload技术可提供更高的安全性和有效性，最大限度地减少脱靶效应，从而改善患者预后。近日，Kivu Bioscience宣布完成9200万美元A轮融资，由Novo Holdings领投，Gimv、Red Tree Venture ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback